NSG 6005 PHARM WEEKS 1-3 QUIZ
(FROM OPERATIONFNP CLASS 11)
TEST WITH 100% CORRECT ANSWERS
Genetic bpolymorphisms baccount bfor bdifferences bin bmetabolism, bincluding:
1. bPoor bmetabolizers, bwho black ba bworking benzyme
2. bIntermediate bmetabolizers, bwho bhave bone bworking, bwild-type ballele band bone
bmutant ballele
3. bExtensive bmetabolizers, bwith btwo bnormally bfunctioning balleles
4. bAll bof bthe babove b- bcorrect banswer-4. bAll bof bthe babove
Up bto b21% bof bAsians bare bultra-rapid b2D6 bmetabolizers, bleading bto:
1. bA bneed bto bmonitor bdrugs bmetabolized bby b2D6 bfor btoxicity
2. bIncreased bdosages bneeded bof bdrugs bmetabolized bby b2D6, bsuch bas bthe
bselective bserotonin breuptake binhibitors
3. bDecreased bconversion bof bcodeine bto bmorphine bby bCYP b2D6
4. bThe bneed bfor blowered bdosages bof bdrugs, bsuch bas bbeta bblockers b- bcorrect
banswer-2. bIncreased bdosages bneeded bof bdrugs bmetabolized bby b2D6, bsuch bas
bthe bselective bserotonin breuptake binhibitors
Rifampin bis ba bnonspecific bCYP450 binducer bthat bmay:
1. bLead bto btoxic blevels bof brifampin band bmust bbe bmonitored bclosely
2. bCause btoxic blevels bof bdrugs, bsuch bas boral bcontraceptives, bwhen
bcoadministered
,3. bInduce bthe bmetabolism bof bdrugs, bsuch bas boral bcontraceptives, bleading bto
btherapeutic bfailure
4. bCause bnonspecific bchanges bin bdrug bmetabolism b- bcorrect banswer-3. bInduce
bthe bmetabolism bof bdrugs, bsuch bas boral bcontraceptives, bleading bto btherapeutic
bfailure
Inhibition bof bP-glycoprotein bby ba bdrug bsuch bas bquinidine bmay blead bto:
1. bDecreased btherapeutic blevels bof bquinidine
2. bIncreased btherapeutic blevels bof bquinidine
3. bDecreased blevels bof ba bcoadministered bdrug, bsuch bas bdigoxin, bthat brequires
bP-
glycoprotein bfor babsorption band belimination
4. bIncreased blevels bof ba bcoadministered bdrug, bsuch bas bdigoxin, bthat brequires
bP-
glycoprotein bfor babsorption band belimination b- bcorrect banswer-4. bIncreased blevels
bof ba bcoadministered bdrug, bsuch bas bdigoxin, bthat brequires bP-
glycoprotein bfor babsorption band belimination
Warfarin bresistance bmay bbe bseen bin bpatients bwith bVCORC1 bmutation, bleading
bto:
1. bToxic blevels bof bwarfarin bbuilding bup
2. bDecreased bresponse bto bwarfarin
3. bIncreased brisk bfor bsignificant bdrug binteractions bwith bwarfarin
4. bLess brisk bof bdrug binteractions bwith bwarfarin b- bcorrect banswer-2. bDecreased
bresponse bto bwarfarin
Genetic btesting bfor bVCORC1 bmutation bto bassess bpotential bwarfarin bresistance
bis brequired bprior bto bprescribing bwarfarin.
1. bTrue
2. bFalse b- bcorrect banswer-2. bFalse
Pharmacogenetic btesting bis brequired bby bthe bU.S. bFood band bDrug bAdministration
bprior bto bprescribing:
1. bErythromycin
2. bDigoxin
3. bCetuximab
,4. bRifampin b- bcorrect banswer-3. bCetuximab
Carbamazepine bhas ba bBlack bBox bWarning brecommending btesting bfor bthe bHLA-
B*1502 ballele bin bpatients bwith bAsian bancestry bprior bto bstarting btherapy bdue bto:
1. bDecreased beffectiveness bof bcarbamazepine bin btreating bseizures bin bAsian
bpatients bwith bthe bHLA-B*1502 ballele
2. bIncreased brisk bfor bdrug binteractions bin bAsian bpatients bwith bthe bHLA-B*1502
ballele
3. bIncreased brisk bfor bStevens-Johnson bsyndrome bin bAsian bpatients bwith bHLA-
B*1502 ballele
4. bPatients bwho bhave bthe bHLA-B*1502 ballele bbeing bmore blikely bto bhave ba
bresistance bto bcarbamazepine b- bcorrect banswer-3. bIncreased brisk bfor bStevens-
Johnson bsyndrome bin bAsian bpatients bwith bHLA-B*1502 ballele
A bgenetic bvariation bin bhow bthe bmetabolite bof bthe bcancer bdrug birinotecan bSN-38
bis binactivated bby bthe bbody bmay blead bto:
1. bDecreased beffectiveness bof birinotecan bin bthe btreatment bof bcancer
2. bIncreased badverse bdrug breactions, bsuch bas bneutropenia
3. bDelayed bmetabolism bof bthe bprodrug birinotecan binto bthe bactive bmetabolite
bSN-38
4. bIncreased bconcerns bfor birinotecan bbeing bcarcinogenic b- bcorrect banswer-2.
bIncreased badverse bdrug breactions, bsuch bas bneutropenia
Patients bwho bhave ba bpoor bmetabolism bphenotype bwill bhave:
1. bSlowed bmetabolism bof ba bprodrug binto ban bactive bdrug, bleading bto
baccumulation bof bprodrug
2. bAccumulation bof binactive bmetabolites bof bdrugs
3. bA bneed bfor bincreased bdosages bof bmedications
4. bIncreased belimination bof ban bactive bdrug b- bcorrect banswer-1. bSlowed
bmetabolism bof ba bprodrug binto ban bactive bdrug, bleading bto baccumulation bof
bprodrug
Ultra-rapid bmetabolizers bof bdrugs bmay bhave:
1. bTo bhave bdosages bof bdrugs badjusted bdownward bto bprevent bdrug
baccumulation
, 2. bActive bdrug brapidly bmetabolized binto binactive bmetabolites, bleading bto
bpotential btherapeutic bfailure
3. bIncreased belimination bof bactive, bnonmetabolized bdrug
4. bSlowed bmetabolism bof ba bprodrug binto ban bactive bdrug, bleading bto ban
baccumulation bof bprodrug b- bcorrect banswer-2. bActive bdrug brapidly bmetabolized
binto binactive bmetabolites, bleading bto bpotential btherapeutic bfailure
A bprovider bmay bconsider btesting bfor bCYP2D6 bvariants bprior bto bstarting
btamoxifen bfor bbreast bcancer bto:
1. bEnsure bthe bpatient bwill bnot bhave bincreased badverse bdrug breactions bto bthe
btamoxifen
2. bIdentify bpotential bdrug-drug binteractions bthat bmay boccur bwith btamoxifen
3. bReduce bthe blikelihood bof btherapeutic bfailure bwith btamoxifen btreatment
4. bIdentify bpoor bmetabolizers bof btamoxifen b- bcorrect banswer-3. bReduce bthe
blikelihood bof btherapeutic bfailure bwith btamoxifen btreatment
The bmost bfrequent btype bof bdrug-food binteraction bis bfood:
1. bCausing bincreased btherapeutic bdrug blevels
2. bAffecting bthe bmetabolism bof bthe bdrug
3. bAltering bthe bvolume bof bdistribution bof bdrugs
4. bAffecting bthe bgastrointestinal babsorption bof bdrugs b- bcorrect banswer-4.
bAffecting bthe bgastrointestinal babsorption bof bdrugs
Food bin bthe bgastrointestinal btract baffects bdrug babsorption bby:
1. bAltering bthe bpH bof bthe bcolon, bwhich bdecreases babsorption
2. bCompeting bwith bthe bdrug bfor bplasma bproteins
3. bAltering bgastric bemptying btime
4. bAltering bthe bpH bof burine b- bcorrect banswer-3. bAltering bgastric bemptying btime
Food bcan balter bthe bpH bof bthe bstomach, bleading bto:
1. bEnhanced bdrug bmetabolism
2. bAltered bvitamin bK babsorption
3. bIncreased bvitamin bD babsorption
(FROM OPERATIONFNP CLASS 11)
TEST WITH 100% CORRECT ANSWERS
Genetic bpolymorphisms baccount bfor bdifferences bin bmetabolism, bincluding:
1. bPoor bmetabolizers, bwho black ba bworking benzyme
2. bIntermediate bmetabolizers, bwho bhave bone bworking, bwild-type ballele band bone
bmutant ballele
3. bExtensive bmetabolizers, bwith btwo bnormally bfunctioning balleles
4. bAll bof bthe babove b- bcorrect banswer-4. bAll bof bthe babove
Up bto b21% bof bAsians bare bultra-rapid b2D6 bmetabolizers, bleading bto:
1. bA bneed bto bmonitor bdrugs bmetabolized bby b2D6 bfor btoxicity
2. bIncreased bdosages bneeded bof bdrugs bmetabolized bby b2D6, bsuch bas bthe
bselective bserotonin breuptake binhibitors
3. bDecreased bconversion bof bcodeine bto bmorphine bby bCYP b2D6
4. bThe bneed bfor blowered bdosages bof bdrugs, bsuch bas bbeta bblockers b- bcorrect
banswer-2. bIncreased bdosages bneeded bof bdrugs bmetabolized bby b2D6, bsuch bas
bthe bselective bserotonin breuptake binhibitors
Rifampin bis ba bnonspecific bCYP450 binducer bthat bmay:
1. bLead bto btoxic blevels bof brifampin band bmust bbe bmonitored bclosely
2. bCause btoxic blevels bof bdrugs, bsuch bas boral bcontraceptives, bwhen
bcoadministered
,3. bInduce bthe bmetabolism bof bdrugs, bsuch bas boral bcontraceptives, bleading bto
btherapeutic bfailure
4. bCause bnonspecific bchanges bin bdrug bmetabolism b- bcorrect banswer-3. bInduce
bthe bmetabolism bof bdrugs, bsuch bas boral bcontraceptives, bleading bto btherapeutic
bfailure
Inhibition bof bP-glycoprotein bby ba bdrug bsuch bas bquinidine bmay blead bto:
1. bDecreased btherapeutic blevels bof bquinidine
2. bIncreased btherapeutic blevels bof bquinidine
3. bDecreased blevels bof ba bcoadministered bdrug, bsuch bas bdigoxin, bthat brequires
bP-
glycoprotein bfor babsorption band belimination
4. bIncreased blevels bof ba bcoadministered bdrug, bsuch bas bdigoxin, bthat brequires
bP-
glycoprotein bfor babsorption band belimination b- bcorrect banswer-4. bIncreased blevels
bof ba bcoadministered bdrug, bsuch bas bdigoxin, bthat brequires bP-
glycoprotein bfor babsorption band belimination
Warfarin bresistance bmay bbe bseen bin bpatients bwith bVCORC1 bmutation, bleading
bto:
1. bToxic blevels bof bwarfarin bbuilding bup
2. bDecreased bresponse bto bwarfarin
3. bIncreased brisk bfor bsignificant bdrug binteractions bwith bwarfarin
4. bLess brisk bof bdrug binteractions bwith bwarfarin b- bcorrect banswer-2. bDecreased
bresponse bto bwarfarin
Genetic btesting bfor bVCORC1 bmutation bto bassess bpotential bwarfarin bresistance
bis brequired bprior bto bprescribing bwarfarin.
1. bTrue
2. bFalse b- bcorrect banswer-2. bFalse
Pharmacogenetic btesting bis brequired bby bthe bU.S. bFood band bDrug bAdministration
bprior bto bprescribing:
1. bErythromycin
2. bDigoxin
3. bCetuximab
,4. bRifampin b- bcorrect banswer-3. bCetuximab
Carbamazepine bhas ba bBlack bBox bWarning brecommending btesting bfor bthe bHLA-
B*1502 ballele bin bpatients bwith bAsian bancestry bprior bto bstarting btherapy bdue bto:
1. bDecreased beffectiveness bof bcarbamazepine bin btreating bseizures bin bAsian
bpatients bwith bthe bHLA-B*1502 ballele
2. bIncreased brisk bfor bdrug binteractions bin bAsian bpatients bwith bthe bHLA-B*1502
ballele
3. bIncreased brisk bfor bStevens-Johnson bsyndrome bin bAsian bpatients bwith bHLA-
B*1502 ballele
4. bPatients bwho bhave bthe bHLA-B*1502 ballele bbeing bmore blikely bto bhave ba
bresistance bto bcarbamazepine b- bcorrect banswer-3. bIncreased brisk bfor bStevens-
Johnson bsyndrome bin bAsian bpatients bwith bHLA-B*1502 ballele
A bgenetic bvariation bin bhow bthe bmetabolite bof bthe bcancer bdrug birinotecan bSN-38
bis binactivated bby bthe bbody bmay blead bto:
1. bDecreased beffectiveness bof birinotecan bin bthe btreatment bof bcancer
2. bIncreased badverse bdrug breactions, bsuch bas bneutropenia
3. bDelayed bmetabolism bof bthe bprodrug birinotecan binto bthe bactive bmetabolite
bSN-38
4. bIncreased bconcerns bfor birinotecan bbeing bcarcinogenic b- bcorrect banswer-2.
bIncreased badverse bdrug breactions, bsuch bas bneutropenia
Patients bwho bhave ba bpoor bmetabolism bphenotype bwill bhave:
1. bSlowed bmetabolism bof ba bprodrug binto ban bactive bdrug, bleading bto
baccumulation bof bprodrug
2. bAccumulation bof binactive bmetabolites bof bdrugs
3. bA bneed bfor bincreased bdosages bof bmedications
4. bIncreased belimination bof ban bactive bdrug b- bcorrect banswer-1. bSlowed
bmetabolism bof ba bprodrug binto ban bactive bdrug, bleading bto baccumulation bof
bprodrug
Ultra-rapid bmetabolizers bof bdrugs bmay bhave:
1. bTo bhave bdosages bof bdrugs badjusted bdownward bto bprevent bdrug
baccumulation
, 2. bActive bdrug brapidly bmetabolized binto binactive bmetabolites, bleading bto
bpotential btherapeutic bfailure
3. bIncreased belimination bof bactive, bnonmetabolized bdrug
4. bSlowed bmetabolism bof ba bprodrug binto ban bactive bdrug, bleading bto ban
baccumulation bof bprodrug b- bcorrect banswer-2. bActive bdrug brapidly bmetabolized
binto binactive bmetabolites, bleading bto bpotential btherapeutic bfailure
A bprovider bmay bconsider btesting bfor bCYP2D6 bvariants bprior bto bstarting
btamoxifen bfor bbreast bcancer bto:
1. bEnsure bthe bpatient bwill bnot bhave bincreased badverse bdrug breactions bto bthe
btamoxifen
2. bIdentify bpotential bdrug-drug binteractions bthat bmay boccur bwith btamoxifen
3. bReduce bthe blikelihood bof btherapeutic bfailure bwith btamoxifen btreatment
4. bIdentify bpoor bmetabolizers bof btamoxifen b- bcorrect banswer-3. bReduce bthe
blikelihood bof btherapeutic bfailure bwith btamoxifen btreatment
The bmost bfrequent btype bof bdrug-food binteraction bis bfood:
1. bCausing bincreased btherapeutic bdrug blevels
2. bAffecting bthe bmetabolism bof bthe bdrug
3. bAltering bthe bvolume bof bdistribution bof bdrugs
4. bAffecting bthe bgastrointestinal babsorption bof bdrugs b- bcorrect banswer-4.
bAffecting bthe bgastrointestinal babsorption bof bdrugs
Food bin bthe bgastrointestinal btract baffects bdrug babsorption bby:
1. bAltering bthe bpH bof bthe bcolon, bwhich bdecreases babsorption
2. bCompeting bwith bthe bdrug bfor bplasma bproteins
3. bAltering bgastric bemptying btime
4. bAltering bthe bpH bof burine b- bcorrect banswer-3. bAltering bgastric bemptying btime
Food bcan balter bthe bpH bof bthe bstomach, bleading bto:
1. bEnhanced bdrug bmetabolism
2. bAltered bvitamin bK babsorption
3. bIncreased bvitamin bD babsorption
